The studies assessed left-ventricular ejection fraction and left-ventricular volume, the two outcomes selected as the focus of the analysis. The investigators used a random-effects meta-analysis to combine the reported results and estimate 95% confidence intervals. Three studies were retrospective and one was prospective, so the pooled finding comes from a small body of observational evidence rather than a large controlled trial.

Across the four studies, 110 patients with cancer therapy–related cardiac dysfunction received CRT. Baseline left-ventricular ejection fraction ranged from 18.6% ± 7.6% to 28.5% ± 3.8%, with an overall mean of 24% ± 7%. After a mean follow-up of 9 ± 5 months, the meta-analysis estimated that left-ventricular ejection fraction increased by 9.95 percentage points, with a 95% confidence interval of 7.79–12.11.

End-systolic volume decreased by 39.17 milliliters, with a 95% confidence interval of 24.99–53.35 mL. These pooled results show improvement in the measured cardiac outcomes among the patients included in the selected studies. Three of the four studies also included control groups composed of patients with other forms of non-ischemic cardiomyopathy who also underwent CRT implantation.

In those comparisons, the improvement in left-ventricular ejection fraction did not differ significantly between the cancer-related group and the other non-ischemic cardiomyopathy group. The authors interpreted the magnitude of reverse remodeling observed in cancer therapy–related cardiac dysfunction as appearing similar to that seen in other non-ischemic causes of cardiac dysfunction. The finding of no significant difference does not, by itself, establish that the groups are equivalent, and the review did not demonstrate superior benefit for either population.

The evidence has important limitations. It was limited to four small observational studies, three of which used retrospective designs, and the participant group was dominated by breast-cancer and lymphoma or leukemia survivors. The pooled results therefore describe imaging-based changes in ventricular function over a mean follow-up of 9 ± 5 months rather than proven improvements in major clinical outcomes.

The authors concluded that CRT may be considered in cancer patients who meet standard criteria for implantation, while emphasizing that the decision should be individualized and guided by multidisciplinary assessment, cancer prognosis and competing clinical risks.

Subject of Research: Effects of cardiac resynchronization therapy on ventricular function in cancer therapy–related cardiac dysfunction

Article Title: Effectiveness of cardiac resynchronization therapy in cancer therapy–related cardiac dysfunction: a systematic review and meta-analysis

Article References: Magalhães, A., Araújo, I., Brabec, M., Menezes, M. N., Fiúza, M., & Caldeira, D. (2026). Effectiveness of cardiac resynchronization therapy in cancer therapy–related cardiac dysfunction: a systematic review and meta-analysis. Supportive Care in Cancer, 34(11), 1133. https://doi.org/10.1007/s00520-026-11364-9

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11364-9

Keywords: cardiac resynchronization therapy, cancer-related cardiac dysfunction, left-ventricular ejection fraction, end-systolic volume, reverse remodeling, cardio-oncology, systematic review, meta-analysis, non-ischemic cardiomyopathy, Effectiveness, cardiac, resynchronization

The systematic review and exploratory meta-analysis, reported in Frontiers in Cardiovascular Medicine, examined multivariable-adjusted predictors of cardiovascular events in adults with multiple myeloma. Researchers searched PubMed, Embase, Web of Science, the Cochrane Library and Ovid MEDLINE from their inception through August 2025, without language restrictions during database searching, although only English-language full texts were considered for eligibility. The protocol followed PRISMA 2020 guidance and was registered in PROSPERO as CRD420251084727. Studies involving cardiac amyloidosis were excluded because the review treated that condition as a distinct, high-risk clinical entity.

Eleven eligible studies were identified from 4,786 records: nine were retrospective cohorts, one was a prospective observational study and one was a retrospective case-control comparison. Five analyses used population-based administrative or cancer-registry data, while six were hospital-based investigations. The studies were conducted in the United States, China, South Korea and Germany, and their sample sizes ranged from 47 to 88,328. Mean or median ages ranged from about 56 to 72 years, reported cardiovascular event counts ranged from 23 to 1,892, and event incidence ranged from 8.3% to 37.6%. Some registry populations may have overlapped, meaning the approximate total of 130,000 patients should not be interpreted as 130,000 fully independent individuals.

Definition of the outcome was one of the review’s main sources of inconsistency. Six studies focused on composite cardiovascular adverse events, three assessed cardiovascular mortality and two examined particular cardiovascular complications. Composite endpoints variously included heart failure, hypertension, ischemic heart disease, myocardial infarction, arrhythmia, pulmonary hypertension, venous thromboembolism, dyspnea, edema, syncope and chest pain. Some events were identified through systematic echocardiography, electrocardiography or cardiac-biomarker testing, whereas others came from claims data, clinical records or standardized diagnostic codes. These differences limited comparability and prevented a broad pooled analysis of all candidate predictors.

Hypertension was the only predictor that met the review’s prespecified requirements for exploratory meta-analysis. Two studies with sufficiently comparable adjusted hazard ratios for incident composite cardiovascular adverse events were combined in a random-effects model. Their pooled hazard ratio was 1.90, with a 95% confidence interval of 1.57 to 2.29; statistical heterogeneity was not detected, with an I-squared value of 0% and a heterogeneity P value of 0.83. A separate hospital cohort reported a consistent direction of association, with an adjusted odds ratio of 2.50 and a 95% confidence interval of 1.10 to 5.90, but it was not pooled because it used an odds ratio rather than a hazard ratio.

Several conventional demographic and clinical signals recurred, although differences in populations, endpoints and statistical methods prevented formal pooling. Male sex was associated with higher cardiovascular mortality in two population-based studies, while older age was linked to cardiovascular events in four analyses. Smoking history was associated with adverse outcomes in two studies: one reported an adjusted odds ratio of 2.80 for composite events, and another reported a hazard ratio of 2.13 for mortality. Low body mass index and obesity were each associated with increased cardiovascular risk in studies that examined both measures. A history of cardiovascular disease pointed toward higher event risk in all four studies that assessed it, reinforcing the distinction between pre-existing vulnerability and treatment-emergent complications.

Clinical measurements supplied some of the largest reported associations, although their precision and interpretation varied. Peripheral arterial occlusive disease was associated with cardiovascular events at a hazard ratio of 10.4, but its wide 95% confidence interval of 1.23 to 89.1 indicates substantial uncertainty. Chronic obstructive pulmonary disease had a smaller reported association, with an adjusted hazard ratio of 1.40 and a 95% confidence interval of 1.03 to 1.90. More advanced disease, represented by Durie–Salmon stage B, was associated with events at a hazard ratio of 2.28 and a 95% confidence interval of 1.30 to 4.00. These estimates came from individual observational studies and should not be treated as interchangeable measures of the same outcome.

Treatment-related findings centered on proteasome inhibitors. In one retrospective comparison of 96 patients receiving bortezomib- or carfilzomib-based therapy, a longer duration of proteasome-inhibitor treatment was associated with higher odds of cardiovascular events, yielding an adjusted odds ratio of 1.94 and a 95% confidence interval of 1.21 to 3.09. A separate prospective observational study of 95 patients with relapsed disease reported a higher cardiovascular-event hazard with carfilzomib-based therapy than with bortezomib-based therapy, with a hazard ratio of 3.00 and a 95% confidence interval of 1.10 to 8.40. These were not pooled because the studies differed in design, treatment context, endpoints and effect measures.

The most striking biomarker signal also came from a single study and has not been independently replicated. Among 95 patients in the prospective multicentre analysis, elevated baseline B-type or N-terminal pro-B-type natriuretic peptide levels were associated with subsequent cardiac events at a hazard ratio of 4.10 and a 95% confidence interval of 2.10 to 8.10. A marked rise in these peptides during the first treatment cycle had an even larger reported association, with a hazard ratio of 9.50 and a 95% confidence interval of 4.30 to 20.70. The result suggests that natriuretic peptides may carry more prognostic information when measured during treatment than at baseline, but the review could not establish monitoring intervals, actionable thresholds or a routine testing strategy.

Methodological limitations constrain how confidently any of these associations can be interpreted. Most studies were judged to have a moderate risk of bias, with recurring problems involving retrospective design, inconsistent cardiovascular definitions and incomplete adjustment for confounders such as baseline cardiovascular disease, renal function, disease stage and cumulative treatment exposure. Several reports also gave unclear accounts of how missing data were handled. Administrative datasets may not capture delivered doses, adherence, outpatient events or subclinical cardiac injury, while small single-center cohorts are difficult to generalize broadly. Publication bias could not be assessed reliably because fewer than 10 studies contributed to a meta-analysis. The findings therefore identify candidate prognostic signals rather than a validated cardiovascular risk score for individual patients.

Overall, the review portrays multiple-myeloma cardiovascular risk as a combination of baseline susceptibility, disease-related effects, treatment exposure and potentially changing markers of cardiac stress. Hypertension is the strongest meta-analytic signal in the available evidence, but age, smoking, prior cardiovascular disease, body size, treatment duration, carfilzomib exposure and dynamic natriuretic peptides may also matter. The authors call for prospective, multicenter studies with standardized cardiovascular endpoints, consistent adjustment for confounding and external validation of prediction models. Such work would be needed before the signals could support individualized monitoring, treatment modification or other clinical decisions. For now, the results sharpen the case for studying cardiovascular risk throughout repeated myeloma therapy rather than treating it as an isolated consequence of a single drug or a one-time assessment at diagnosis.

Subject of Research: Systematic review of cardiovascular-event predictors in adults with multiple myeloma

Article Title: Predictors of cardiovascular events in multiple myeloma: a systematic review and exploratory meta-analysis

Article References: Lv, T., Liu, M., Zhang, W., Zhang, J., & Fang, Y. (2026). Predictors of cardiovascular events in multiple myeloma: a systematic review and exploratory meta-analysis. Frontiers in Cardiovascular Medicine, 13, Article 1925889. https://doi.org/10.3389/fcvm.2026.1925889

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1925889

Keywords: multiple myeloma, cardiovascular risk, hypertension, cardio-oncology, carfilzomib, proteasome inhibitors, natriuretic peptides, systematic review, meta-analysis, Predictors, cardiovascular, events

Anthracyclines, including doxorubicin and epirubicin, are among the most effective chemotherapy agents available for breast cancer, but they carry a well-documented risk of cardiotoxicity. These drugs interfere with topoisomerase II and generate reactive oxygen species within cardiac mitochondria, leading to progressive myocyte injury, cell death, and ultimately a decline in left ventricular function. Cancer therapy-related cardiac dysfunction, abbreviated CTRCD, can manifest during treatment or emerge years later, significantly increasing cardiovascular morbidity and mortality among cancer survivors. Because breast cancer patients frequently receive anthracycline regimens and often live decades beyond their diagnosis, preventing even subtle early cardiac damage has become a central goal of cardio-oncology care.

Exercise has emerged as a candidate intervention precisely because it counteracts several of the mechanisms through which anthracyclines injure the heart. Preclinical research suggests that regular physical activity improves mitochondrial function, enhances antioxidant defenses, and promotes angiogenesis, all of which may buffer cardiomyocytes against chemotherapy-induced stress. Clinical guidelines from the European Society of Cardiology on cardio-oncology acknowledge the theoretical rationale for exercise-based cardioprotection, yet previous reviews have largely examined heterogeneous cancer populations receiving varied treatments, making it difficult to isolate the specific effect of exercise on anthracycline-induced cardiac dysfunction in breast cancer patients. The Spanish research team set out to close that gap with a rigorously focused analysis.

To do so, the investigators conducted a comprehensive search of PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and Web of Science. They applied strict eligibility criteria: studies had to be randomized controlled trials including breast cancer patients undergoing anthracycline-based chemotherapy, the exercise intervention had to last at least twelve weeks with at least one session per week, and each trial had to report at least one of five prespecified outcomes. Those outcomes were left ventricular ejection fraction, global longitudinal strain, cardiac troponin I, cardiac troponin T, and N-terminal prohormone of brain natriuretic peptide, commonly known as NT-proBNP. Together, these markers capture different dimensions of cardiac injury, from pumping capacity and myocardial deformation to biochemical evidence of myocyte damage and neurohormonal activation.

After screening and quality assessment, six randomized controlled trials totaling 360 participants met the inclusion criteria. The meta-analysis revealed that exercise significantly attenuated the elevation of cardiac troponin I compared with usual cancer care, with a standardized mean difference of −0.50 and a 95 percent confidence interval spanning −0.93 to −0.06, yielding a p value of 0.02. Cardiac troponin I is a protein released when heart muscle cells are injured, and elevated levels during chemotherapy are among the earliest biochemical indicators of myocardial damage. The fact that exercising patients showed measurably lower troponin I elevations suggests that physical training may genuinely reduce the degree of acute myocyte injury caused by anthracyclines, rather than merely masking symptoms after damage has occurred.

However, the picture becomes more complicated when the other outcomes are considered. The analysis found no statistically significant between-group differences for left ventricular ejection fraction, the standard echocardiographic measure of pumping efficiency; for global longitudinal strain, a more sensitive deformation-based imaging metric; for cardiac troponin T, a related but structurally distinct isoform; or for NT-proBNP, a hormone released when the heart is under hemodynamic stress. This pattern is intriguing from a mechanistic standpoint. Troponin I reflects early cellular injury, whereas ejection fraction and strain measure functional consequences that may take longer to develop or may require larger sample sizes to detect reliably. It is possible that exercise protects cardiomyocytes at the biochemical level before those protective effects translate into measurable preservation of pump function, but the current evidence cannot confirm that sequence.

The authors are careful to frame their conclusion appropriately. They state that the cardioprotective role of exercise during anthracycline treatment remains uncertain, though the attenuation of cardiac troponin I elevation suggests a potential protective signal warranting further investigation. This nuanced position reflects the realities of the underlying evidence base. Six trials with 360 participants is a modest foundation for meta-analysis, and the individual studies varied in exercise modality, intensity, duration, and supervision. Some trials employed supervised aerobic training, others combined aerobic and resistance elements, and the timing of assessments relative to chemotherapy cycles differed across studies. Such heterogeneity, even among trials meeting strict inclusion criteria, can dilute true effects and widen confidence intervals.

The broader context of cardio-oncology research reinforces both the promise and the limitations of these findings. Earlier systematic reviews, including work by Zhang and colleagues in 2025 and Murray and colleagues in 2022, have generally reported favorable trends for exercise on cardiac outcomes in breast cancer patients, but they too have been constrained by small sample sizes and inconsistent outcome definitions. The European Society of Cardiology guidelines published in 2022 established biomarker criteria for diagnosing CTRCD, and subsequent research by Mecinaj and colleagues in 2024 demonstrated that applying those criteria changes the apparent incidence of cardiac dysfunction in treated populations. Standardization of both imaging and biomarker endpoints remains an unfinished project, and until it is completed, meta-analyses will continue to grapple with heterogeneous data.

What makes the current study particularly valuable is its exclusive focus on anthracycline-treated breast cancer patients, a population in which the cardiotoxic insult is relatively well characterized and the therapeutic window for intervention is clearly defined. By restricting inclusion to trials with interventions lasting at least twelve weeks and comparing exercise against usual cancer care, the Spanish team reduced some sources of noise that have plagued earlier reviews. The finding that troponin I, arguably the most mechanistically proximal biomarker of anthracycline injury, responded to exercise while more distal functional measures did not is biologically plausible and consistent with the understanding that subcellular damage precedes overt systolic dysfunction, sometimes by years.

Looking forward, the authors call for larger, standardized trials employing advanced assessment modalities and longer follow-up periods. Techniques such as stress echocardiography, cardiac magnetic resonance imaging with T1 mapping, and high-sensitivity troponin assays could detect subtler degrees of myocardial injury and dysfunction than conventional resting echocardiography. Longer follow-up is equally critical, because anthracycline cardiotoxicity can progress insidiously over a decade or more after exposure. Meanwhile, the ICOS-CORE working group, an international collaboration focused on cardio-oncology rehabilitation and exercise, published evidence priorities in 2025 aimed at establishing research standards for the field, signaling growing momentum behind precisely the kind of rigorous investigation this meta-analysis advocates. For now, breast cancer patients receiving anthracyclines should discuss exercise with their oncology and cardiology teams, balancing the encouraging troponin I signal against the honest uncertainty that still surrounds exercise as a proven cardioprotective therapy.

Subject of Research: Exercise training as a cardioprotective intervention against anthracycline-induced cardiac dysfunction in breast cancer patients

Article Title: Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis

Article References: Marín, A. J., García-Coll, M. V., Moraleda, E. M., Castellanos-Montealegre, M., & Laín, S. A. (2026). Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis. Supportive Care in Cancer, 34(10), Article 928. https://doi.org/10.1007/s00520-026-11085-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11085-z

Keywords: breast cancer, anthracyclines, cardiotoxicity, exercise, cardiac troponin I, cancer therapy-related cardiac dysfunction, cardio-oncology, meta-analysis, left ventricular ejection fraction, global longitudinal strain, NT-proBNP, chemotherapy

The central methodological challenge is counterfactual reasoning. Observational clinical records contain outcomes only for the care actually received; the outcomes that would have occurred under an alternative strategy remain unobserved. Existing nursing care evaluations, the authors note, primarily characterize population-level associations or predict observed outcomes, but they do not estimate the potential outcomes of individual patients under standard and enhanced acute care while accounting for evolving clinical states and predictive uncertainty. The Counterfactual Event Planner addresses this gap by integrating five components: the Manifold-Based Decision Model, the Agent-Based Contextual Navigator, the Probabilistic Outcome Synthesizer, the Counterfactual Pacing Strategy, and Bayesian Outcome Updating. Together, these modules construct clinically meaningful latent representations of patient health, explore context-aware intervention trajectories, estimate potential outcome distributions, and refine those estimates as new clinical evidence arrives.

The clinical motivation is grounded in the growing field of cardio-oncology. Cancer treatment may interact with baseline cardiovascular conditions, acute physiological stress, and supportive care requirements, increasing the need for timely nursing assessment and coordinated risk management. The authors deliberately selected oncology patients with pre-existing cardiovascular risk factors as the initial validation group for both clinical and methodological reasons. Clinically, this population is particularly vulnerable because concurrent clinical needs may affect treatment tolerance, symptom burden, care coordination, and long-term outcomes. Methodologically, a population with a higher expected burden of cardiovascular events provides a clearer setting for estimating heterogeneous care effects and comparing alternative nursing strategies while reducing the influence of severe outcome sparsity. The authors emphasize that this targeted population should be interpreted as an initial validation group rather than the only population that may benefit, since cardiovascular toxicity may also occur among patients initially classified as low risk.

Technically, the framework begins with the Manifold-Based Decision Model, which encodes demographic, oncological, cardiovascular, physiological, treatment, and nursing variables recorded during the first 24 hours of intensive care admission into a clinically informed latent patient state. The encoder maps high-dimensional clinical features onto a 64-dimensional manifold, capturing nonlinear dependencies among laboratory measurements, vital signs, and demographic attributes while reducing noise and redundancy. In implementation, the encoder is trained on standardized structured variables from the MIMIC-IV training cohort, and the decoder reconstructs observed clinical variables under an observed feature mask, preventing imputed or unavailable measurements from dominating representation learning. The same fitted preprocessing statistics and encoder parameters are then applied unchanged to validation, internal test, and external cohorts, a design choice that guards against information leakage.

The Agent-Based Contextual Navigator then operates on this encoded representation. Four agents, each governed by a policy network conditioned on patient history and current clinical observations, explore feasible intervention trajectories under two predefined acute care strategies: standard acute care and enhanced acute care. Enhanced acute care is assigned when a composite score of early nursing intensity, physiological monitoring frequency, and supportive care reaches the median threshold calculated from the MIMIC-IV training cohort. Crucially, the navigator is not optimized through online trial and error with patients. The action space is restricted to clinically observed strategies, and policy and transition parameters are learned offline from observed care assignments, baseline covariates, temporal nursing records, and outcome labels. This preserves clinical feasibility and avoids simulated interventions outside the range of observed nursing practice.

The Probabilistic Outcome Synthesizer assigns strategy-specific outcome distributions to the candidate trajectories. The clinical outcome vector includes intensive care unit mortality, in-hospital mortality, cardiovascular adverse events, intensive care unit length of stay, and clinical recovery status. Binary endpoints such as mortality and cardiovascular adverse events are modeled using Bernoulli likelihoods, while continuous endpoints such as length of stay and recovery scores use Gaussian likelihoods with learned means and variances. The Counterfactual Pacing Strategy generates one patient trajectory under each acute care strategy from the same baseline state, imposing temporal and clinical constraints so that simulated trajectories remain physiologically plausible. Bayesian Outcome Updating maintains a diagonal Gaussian posterior over the latent health state and performs one posterior update after every hourly observation, continuously refining outcome estimates and predictive uncertainty as additional data becomes available.

The empirical evaluation drew on two public critical care electronic health record resources. MIMIC-IV, containing 299,712 patients, 431,231 hospital admissions, and 73,181 intensive care unit stays from a tertiary academic medical center, was used for model development, training, validation, and internal testing. The eICU Collaborative Research Database, containing 200,859 intensive care unit encounters from 139,367 patients treated at 208 hospitals across the United States, was reserved exclusively for external validation. The eligible MIMIC-IV oncology cohort contained 8,640 intensive care encounters, split at the patient level into 6,912 training, 864 validation, and 864 internal test records, while the eligible eICU cohort contained 9,760 encounters. Adult oncology patients aged at least 18 years were retained when cancer diagnosis, intensive care admission, cardiovascular risk information, and complete outcome records were available, with encounters shorter than 24 hours excluded.

The results show consistent advantages over six representative baselines spanning traditional statistics, conventional causal inference, deep learning, causal representation learning, and tree-based estimation: Logistic Regression, Propensity Score Matching, Multi-Layer Perceptron, TARNet, DragonNet, and Causal Forest. On the MIMIC-IV internal test cohort, the Counterfactual Event Planner achieved a Precision in Estimation of Heterogeneous Effect of 0.099 compared with 0.111 for DragonNet, the strongest baseline, a relative reduction of 10.8 percent. Average Treatment Effect Error fell from 0.022 to 0.018, an 18.2 percent relative reduction, and Policy Value Error dropped from 0.027 to 0.023, a 14.8 percent improvement. Factual outcome prediction also improved, with root mean squared error of 0.185 and mean absolute error of 0.134 versus 0.192 and 0.139 for DragonNet. On the external eICU cohort, evaluated without retraining or cohort-specific adjustment, the framework again achieved the lowest error on every metric, indicating robust cross-hospital generalization under changes in patient composition, clinical practice, and measurement patterns.

Two additional validation strategies strengthened the evidence. In semi-synthetic counterfactual experiments, where real clinical covariates were retained but treatment assignment and potential outcomes were generated through predefined nonlinear causal mechanisms, the framework reduced true individual treatment effect error relative to DragonNet by 14.1, 17.8, and 23.0 percent under low, moderate, and strong confounding on MIMIC-IV, with corresponding external reductions of 14.9, 16.8, and 20.8 percent. The increasing improvement under stronger confounding suggests greater robustness when treatment assignment is strongly associated with baseline severity. A longitudinal landmark analysis at 6, 12, 18, and 24 hours showed that performance improved as clinical information accumulated, with PEHE on MIMIC-IV decreasing from 0.121 at 6 hours to 0.099 at 24 hours, and temporal consistency of individual effect estimates stabilizing over the observation window. An ablation study confirmed that removing the Counterfactual Pacing Strategy produced the largest degradation, underscoring the value of explicitly generating alternative care trajectories from a shared baseline state.

Beyond computational performance, the study incorporated a participatory clinical acceptability assessment in which specialist oncology nurses reviewed care strategy definitions, cardiovascular risk indicators, outcome variables, and representative counterfactual outputs. The framework received favorable ratings across clinical relevance, interpretability, workflow compatibility, and perceived safety, with an overall acceptability score of 4.38 on a five-point Likert scale and an 85.4 percent agreement rate. The authors position the work within the T1 to T2 translational stage, meaning computational discovery and retrospective validation, and explicitly state that prospective T3 and T4 studies examining workflow integration, alert burden, equity, and population-level impact remain necessary. They caution that estimated counterfactual outcomes should be regarded as decision support evidence requiring clinical interpretation rather than definitive causal truth, and that the framework is intended to support nurse-led assessment, risk stratification, and interdisciplinary care planning while final care decisions remain under clinician supervision and institutional protocols. If prospective validation succeeds, the approach could mark a shift from population-level nursing care evaluation toward genuinely individualized assessment for cancer patients whose hearts are on the line.

Subject of Research: Counterfactual machine learning for individualized nursing care assessment in oncology patients with cardiovascular risk factors

Article Title: Translational assessment of nursing care models for oncology patients with cardiovascular risk factors

Article References: Du, H., Wang, J., & Xing, Y. (2026). Translational assessment of nursing care models for oncology patients with cardiovascular risk factors. Frontiers in Cardiovascular Medicine, 13, Article 1834086. https://doi.org/10.3389/fcvm.2026.1834086

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1834086

Keywords: counterfactual event planner, oncology nursing, cardiovascular risk factors, individualized treatment effect, MIMIC-IV, eICU database, causal inference, electronic health records, cardio-oncology, Bayesian outcome updating, critical care, clinical decision support

Now, a team of researchers from the University of Szeged in Hungary and the Medical University of Vienna in Austria has reported that a synthetic version of an embryo-derived peptide may protect the heart from radiation damage while potentially preserving, and even enhancing, the anti-cancer efficacy of radiotherapy. The peptide in question is preimplantation factor, or PIF, an evolutionarily conserved 15-amino-acid peptide secreted by viable mammalian embryos. In pregnancy, PIF plays a critical role in maternal tolerance of the fetal allograft, providing integrated local and systemic immune protection, transplant acceptance, and controlled cell and organ growth. It supports embryo implantation by modulating cell proliferation and apoptosis, and it exhibits immunomodulatory, anti-inflammatory, and regenerative properties. The lessons learned from pregnancy have been translated to non-pregnancy applications, including neurologic diseases, atherosclerosis, and radiation protection, and a synthetic PIF analog containing the same amino acid sequence as the native peptide has already shown protective effects against neuroinflammation, type 1 diabetes, Duchenne muscular dystrophy, and acute radiation syndrome.

In the new study, published in Frontiers in Cardiovascular Medicine, the researchers investigated whether synthetic PIF, or sPIF, could mitigate the development of radiation-induced heart disease in rats. Adult male Sprague-Dawley rats were allocated into three experimental groups: a vehicle-treated control group, a vehicle-treated radiotherapy group receiving a single focused dose of 50 Gy to the heart, and a radiotherapy group treated with sPIF. The animals were monitored at one, three, and fifteen weeks after irradiation, reflecting the acute, subacute, and chronic phases of radiation injury. Endpoint assessments included transthoracic echocardiography, histopathology, quantitative polymerase chain reaction, Western blotting, and ultra-high-performance liquid chromatography-tandem mass spectrometry in left ventricular samples. The sPIF was administered subcutaneously at 1 mg/kg, a dose selected based on previous dose-finding experiments and on preclinical models in which 0.1 to 1 mg/kg had maximum efficacy. Treatment began daily for the first two weeks and continued twice weekly thereafter, an approach adapted from previous episodic sPIF administration in experimental autoimmune encephalomyelitis models.

The results were striking. At week three, sPIF treatment markedly reduced left ventricular overexpression of the pro-inflammatory cytokines interleukin-1 and interleukin-6, as well as the pro-survival and anti-inflammatory signal transducer and activator of transcription 3, compared with the vehicle-treated control group. This early anti-inflammatory effect presumably enabled fibrosis prevention at fifteen weeks. At the same time, the sPIF-treated radiotherapy group exhibited marked reductions in left ventricular end-diastolic and end-systolic diameters compared with the vehicle-treated control or radiotherapy groups, accompanied by increased long-axis fractional shortening. The radiotherapy-induced diastolic dysfunction observed at week three, indicated by reduced mitral annulus velocity and elevated E/e’ ratio, was markedly reduced by sPIF treatment. By week fifteen, the vehicle-treated radiotherapy group had developed concentric left ventricular hypertrophy, with significantly increased septal, posterior, and anterior wall thicknesses and relative wall thickness, as well as prolonged isovolumic relaxation time and elevated Tei index, all indicating diastolic dysfunction. sPIF treatment partially reversed these irradiation-induced changes, reflected by significant reductions in wall thicknesses and relative wall thickness, improvement in left ventricular dimensions and fractional shortening, and normalization of diastolic functional parameters.

At the cellular level, the protective effects were equally evident. At week fifteen, cardiomyocytes in the vehicle-treated radiotherapy group showed significantly increased perimeter and cross-sectional area, confirming the development of compensatory hypertrophy. Notably, there were no marked differences in cardiomyocyte perimeters and cross-sectional areas between the sPIF-treated radiotherapy group and the vehicle-treated control group at week fifteen. Molecular analysis revealed that the vehicle-treated radiotherapy group had significantly reduced expression of the adult myosin heavy chain alpha-isoform, Myh6, and a markedly higher Myh7/Myh6 ratio, indicating molecular signs of left ventricular hypertrophy development. sPIF preserved healthy adult myosin heavy chain isoform content compared with the vehicle-treated radiotherapy group. The researchers also found that sPIF treatment significantly mitigated the radiotherapy-induced reduction of left ventricular sarcoendoplasmic reticulum calcium ATPase 2a isoform, or SERCA2a, protein level at week fifteen. More preclinical studies have found a significant inverse correlation between SERCA2a gene expression and isovolumic relaxation time, indicating impaired relaxation and a potential association with heart failure with preserved ejection fraction.

Beyond hypertrophy, sPIF treatment alleviated the radiotherapy-associated cardiac fibrosis. At week fifteen, sPIF significantly reduced left ventricular expression of connective tissue growth factor and protein levels of SMAD2/3, key mediators of the transforming growth factor-beta1 pathway considered the central molecular mechanism in radiation-induced cardiac fibrosis. sPIF also significantly decreased left ventricular fibrosis at week fifteen and mitigated overexpression of A-type natriuretic peptide, a myocardial stretch marker. The antioxidant properties of sPIF were reflected in significantly reduced nitrotyrosine levels, a marker of nitro-oxidative stress, in the left ventricles after sPIF treatment compared with the vehicle-treated radiotherapy group at week fifteen. The left ventricular riboflavin content, a cofactor of the antioxidant glutathione redox cycle, remained markedly higher in the sPIF-treated radiotherapy group compared with the vehicle-treated control group. The nicotinamide adenine dinucleotide levels were markedly higher in the sPIF-treated radiotherapy group at week fifteen compared to the time-matched vehicle-treated control groups, supporting antioxidant mechanisms by increasing glutathione levels and antioxidant enzyme activity.

The cardioprotective effects of sPIF were further validated in vitro. In H9c2 cardiomyoblasts, sPIF suppressed angiotensin II-induced hypertrophy, with the cell size of sPIF-treated cardiomyoblasts being significantly smaller compared to the angiotensin II-treated group. The co-treatment with sPIF markedly counterbalanced the reduced viability of H9c2 cardiomyoblasts exposed to hydrogen peroxide-induced oxidative stress. In human ventricular cardiac fibroblasts, sPIF treatment significantly reduced collagen-I and alpha-smooth muscle actin protein expression after exposure to transforming growth factor-beta1. Scratch assays revealed a biphasic influence of transforming growth factor-beta1 on cardiac fibroblast motility, with transient enhancement of migration in the early phase after scratching but marked delay in the later phases, reflecting its canonical induction of myofibroblast differentiation, stress fiber assembly, and excessive extracellular matrix deposition. sPIF significantly supported migration in the early phase and appeared to abrogate the late inhibitory action of transforming growth factor-beta1, suggesting a role in modulating fibroblast-driven repair while mitigating maladaptive fibrosis.

Perhaps most importantly for cancer patients, sPIF did not interfere with the anti-cancer efficacy of radiotherapy. In three different human breast carcinoma cell lines, MCF-7, T47D, and MDA-MB-231, none of the tested concentrations of sPIF increased cell proliferation within 72 hours. Moreover, sPIF intensified the anti-proliferative effect of radiotherapy in breast cancer cell lines compared to radiotherapy alone. This finding is in line with previously reported sPIF-induced anti-neoplastic effects and suggests that sPIF may serve as a potential dual cardioprotective and anti-proliferative agent. The researchers hypothesized that the enhanced acute inflammation induced by sPIF in the early phase might facilitate the elimination of tissue debris and contribute to the earlier start of adaptive mechanisms and wound healing processes, mainly due to the immunomodulatory effects of the peptide. By week fifteen, sPIF appeared to prevent chronic cell death and limit harmful remodeling in radiation-induced heart disease.

Mechanistically, sPIF primarily targets protein disulfide isomerase/thioredoxin and heat shock proteins, thereby reducing oxidative stress and protein misfolding and preventing cellular damage. These targeted protective mechanisms are key in addressing radiotherapy-induced organ damage. sPIF has been reported as a robust immunomodulator and cellular protector in acute radiation syndrome by binding to innate immune cells such as macrophages and neutrophils, suppressing inflammatory mediators such as tumor necrosis factor-alpha and inducible nitric oxide synthase, and promoting a tolerant, balanced immune profile. It regulates innate immunity by blocking voltage-gated potassium channels, thereby reducing overactivity of neutrophils and natural killer cells without broad immune depletion, and selectively tunes adaptive immunity by inhibiting pro-inflammatory pathways like IL-23 and IL-17a-mediated signaling, thereby reducing toxicity but preserving infection defense. Notably, sPIF has been tested in Fast Track FDA human clinical trials for autoimmune disease, demonstrating safety and the absence of adverse drug-drug interactions, and has received FDA orphan drug designation for acute radiation syndrome.

The authors recognize several limitations of the current study. Significant differences exist in the pathomechanisms of experimental and clinical radiation-induced heart disease, comprising species-, sex-, and age-related attributes, as well as the absence of tumors, atherosclerosis, and other cardiovascular risk factors. To avoid cycle- and hormone-dependent protective effects, the researchers opted to use only male rats. Moreover, the therapeutic effects of sPIF were tested in a healthy adolescent rat model, which represents an additional limitation. Single-dose irradiation models differ from clinical radiotherapy, which typically uses multiple smaller fractions, and single doses can exaggerate and accelerate tissue damage in preclinical models. The researchers acknowledge that findings from single-dose models might have limited translational relevance, although they note that in modern radiotherapy practice, very high doses are used in stereotactic radiosurgery, and their findings may also apply to that field. Animal models incorporating both sexes, mediastinal tumors or breast cancer, cardiovascular risk factors, comorbidities, and advanced age would more closely recapitulate the clinical setting of radiation-induced heart disease.

Despite these limitations, the study identified sPIF as a novel, promising, druggable candidate for preventing and improving the signs of radiation-induced heart disease. The researchers emphasize that the exact initiating targets and upstream signaling mechanisms of sPIF in radiation-induced heart disease remain unexplored, and that transforming growth factor-beta/SMAD signaling and SERCA2a preservation are correlative biomarkers rather than definitive proof of direct mechanisms. Future preclinical studies could clarify the cardioprotective and anti-neoplastic mechanisms of sPIF and its direct mechanistic links to nitro-oxidative stress, inflammation, fibrosis, and apoptosis in radiation-induced heart disease. Given its effectiveness in preclinical models, sPIF could be a valuable addition to cancer radiotherapy regimens and warrants further exploration of its safety and efficacy in human trials. For the growing population of cancer survivors living with the cardiovascular consequences of their life-saving treatment, the prospect of a pregnancy-derived peptide that shields the heart without weakening the anti-cancer beam represents a genuinely new direction in cardio-oncology.

Subject of Research: Cardio-Oncology

Article Title: Synthetic preimplantation factor ameliorates the severity of radiotherapy-induced heart disease in a rat model

Article References: Kovács, M. G., Antunes Goncalves, A. I., Varga, Z., Losonczi, R., Kupecz, K., Volford, D., Pósa, S. P., Minorics, R., Galla, Z., Zins, K., Sejben, A., Kriston, A., Kovács, F., Horváth, P., Monostori, P., Cserni, G., Zupkó, I., Podesser, B. K., Barnea, E. R., … Sárközy, M. (2026). Synthetic preimplantation factor ameliorates the severity of radiotherapy-induced heart disease in a rat model. Frontiers in Cardiovascular Medicine, 13, Article 1946843. https://doi.org/10.3389/fcvm.2026.1946843

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1946843

Keywords: radiation-induced heart disease, synthetic preimplantation factor, cardioprotection, radiotherapy, cardio-oncology, cardiac fibrosis, diastolic dysfunction, left ventricular hypertrophy, nitro-oxidative stress, breast cancer, Synthetic, preimplantation

The clinical stakes are enormous. Up to a quarter of patients treated with doxorubicin develop cardiac injury during or after therapy, ranging from silent myocardial damage to full-blown congestive heart failure. The risk climbs steeply with cumulative dose: at 400 mg/m² the incidence of heart failure hovers around 5 percent, but it jumps to roughly 26 percent at 550 mg/m² and a staggering 48 percent at 700 mg/m². Dexrazoxane remains the only FDA-approved cardioprotective agent, yet concerns about whether it might blunt doxorubicin’s anticancer power have limited its use. Beta-blockers and other supportive measures help some patients, but none directly address the fundamental breakdown in cellular housekeeping that Tian and colleagues identify as central to the disease.

To understand why the heart is so vulnerable, one must appreciate its cellular architecture. Cardiomyocytes are packed with mitochondria — the power plants that fuel continuous contraction — and with the sarcoplasmic reticulum, a specialized endoplasmic reticulum that stores and releases the calcium ions triggering each heartbeat. Doxorubicin attacks both. It intercalates into DNA and traps topoisomerase IIβ in lethal cleavage complexes, generating persistent double-strand breaks. Simultaneously, it disrupts iron metabolism and drives redox cycling, flooding cells with reactive oxygen species. The mitochondria swell, their cristae collapse, and their DNA mutates. The ER loses its ability to fold proteins properly and to buffer calcium. These twin injuries converge on the same problem: the cell’s recycling systems must somehow keep pace with escalating damage.

Mitophagy is the cell’s way of selectively devouring broken mitochondria. When a mitochondrion loses its membrane potential, a protein called PINK1 accumulates on its outer surface and recruits Parkin, which tags the organelle with ubiquitin chains that autophagy receptors like p62 and optineurin recognize. Alternatively, receptor proteins such as BNIP3, NIX, and FUNDC1 can bind LC3 directly on forming autophagosomes, bypassing the ubiquitin step entirely. Either route ends with the damaged mitochondrion sealed inside an autophagosome, fused with a lysosome, and digested. But here is where the review delivers its most provocative insight: doxorubicin does not simply switch mitophagy on or off. Instead, it disrupts the process at multiple checkpoints — damage sensing, cargo labeling, autophagosome formation, and lysosomal degradation — and the outcome depends entirely on which checkpoint fails first.

The authors marshal evidence from dozens of preclinical studies to build this checkpoint-dependent framework. In some models, low doses of doxorubicin trigger a compensatory mitophagy response that genuinely protects the heart by clearing damaged mitochondria before they accumulate. In others, the drug drives excessive mitochondrial fragmentation through the fission protein DRP1, creating a feed-forward loop in which Parkin recruitment accelerates fission, which in turn generates more fragments for mitophagy to consume — eventually depleting the cell’s mitochondrial reserve faster than it can be replaced. Still other studies reveal a third failure mode: cytosolic p53, elevated by doxorubicin, binds Parkin and prevents it from reaching mitochondria, starving the pathway at its very first step. And in models where flux has been directly measured, autophagosomes pile up because the final fusion with lysosomes never happens, leaving damaged organelles stranded inside cellular garbage bags that never get emptied.

What makes this framework so powerful is that it explains decades of apparently contradictory findings. Studies reporting that doxorubicin

The apparent contradictions in the literature become even more tractable when one considers how experimental design shapes what investigators observe. The review emphasizes that discrepancies among studies reporting protective organelle clearance, insufficient autophagy initiation, or stalled degradation may reflect differences in doxorubicin dose, exposure duration, and exposure pattern, as well as the choice of experimental model and whether autophagic flux was actually measured rather than inferred. A single time point showing abundant autophagosomes, for instance, could indicate either vigorous recycling or a jammed disposal system; only dynamic flux assays can distinguish between these possibilities. Many earlier studies relied on static markers such as LC3-II abundance or puncta formation, which cannot by themselves reveal whether cargo ultimately reaches the lysosome. This methodological blind spot may account for a substantial fraction of the conflicting conclusions that have accumulated over the years, and it underscores the review’s call for standardized flux assessment in future work.

ER-phagy, the selective degradation of endoplasmic reticulum through autophagy, receives comparatively less experimental attention in the doxorubicin setting, and the authors are careful to frame the available evidence cautiously. Receptor proteins such as FAM134B, RTN3, ATL3, and TEX264 can each recognize stressed or damaged ER fragments and deliver them to autophagosomes, but the specific contributions of these receptors in cardiomyocytes exposed to anthracyclines remain incompletely mapped. Existing studies differ in the doxorubicin regimens employed, the receptor pathways interrogated, and the rigor of flux measurement, making direct comparison difficult. The review therefore proposes functional divergence of ER-phagy as an interpretive framework rather than a settled conclusion: in some contexts ER-phagy may relieve stress by clearing misfolded protein aggregates and damaged reticular membranes, while in others it may strip the cell of calcium-handling capacity at the sarcoplasmic reticulum, worsening contractile dysfunction. Disentangling these possibilities will require receptor-specific tools and longitudinal designs that current literature largely lacks.

A further layer of complexity arises from the physical intimacy of the two organelles. Mitochondria-associated ER membranes, or MAMs, are contact sites where the ER and mitochondria lie within tens of nanometers of each other, tethered by protein complexes that coordinate calcium transfer, mitochondrial dynamics, and stress signaling. In healthy cardiomyocytes, these junctions allow efficient shuttling of calcium ions from the sarcoplasmic reticulum into mitochondria to match energy production with contractile demand. Doxorubicin disrupts this architecture, and the review argues that MAM dysfunction may serve as the mechanistic hinge connecting mitochondrial injury, ER stress, and selective autophagy imbalance. Receptors involved in mitophagy and ER-phagy localize at or near these contact sites, and autophagosome formation itself can be coordinated there. If MAM integrity deteriorates, calcium mishandling, energetic failure, and defective organelle quality control may reinforce one another, producing a vicious cycle that no single-pathway intervention is likely to break.

When mitochondrial clearance fails, the consequences extend beyond energy depletion. Damaged mitochondria that persist within cardiomyocytes can leak mitochondrial DNA into the cytosol and release mitochondrial reactive oxygen species, both of which activate inflammatory signaling through the cGAS-STING pathway and the NLRP3 inflammasome. This places mitophagy at the interface between organelle quality control and innate immunity, suggesting that failed clearance may convert a purely metabolic injury into a sterile inflammatory process that accelerates myocardial damage. Such a mechanism could help explain why cardiac injury after doxorubicin sometimes progresses long after the drug has been cleared from the body, and why late-onset cardiotoxicity, with a reported mean latency of approximately seven years, remains so difficult to predict or prevent.

The temporal dimension of doxorubicin-induced cardiotoxicity adds another consideration for translational efforts. Acute injury occurring within hours to days of exposure is often at least partly reversible and involves vacuolar change, interstitial edema, and inflammatory infiltration. Early-onset chronic disease emerges within a year and represents the most common clinically relevant pattern, evolving from subclinical dysfunction toward overt heart failure. Late-onset disease can surface years or even decades later, with restrictive cardiomyopathy appearing relatively more frequently and reflecting progressive fibrosis and myofibrillar disorganization following cardiomyocyte death. Because the dominant injury mechanisms and the state of the autophagy machinery likely differ across these phases, a cardioprotective strategy effective during acute exposure may prove useless or even harmful when applied years afterward. Stage-specific targeting of mitophagy and ER-phagy therefore emerges as a central theme of the review.

Subtle structural changes may also serve as early warning signs that current monitoring overlooks. Reductions in left ventricular mass have been observed after doxorubicin exposure in both experimental models and clinical cohorts, and this change can precede any measurable decline in ejection fraction while persisting for at least six months. Such remodeling suggests that functional indices alone capture the injury process late. Combination regimens modify the phenotype further: doxorubicin plus trastuzumab has been associated with reduced cardiac mass and biventricular dysfunction even without severe metabolic abnormalities or very high cumulative anthracycline exposure, and prior anthracycline treatment appears to increase susceptibility to trastuzumab-related cardiotoxicity, possibly through overlapping disruption of mitochondrial quality control.

The review is candid about the limits of the evidence base. Most of what is known about mitophagy and ER-phagy in this setting derives from cell culture and animal studies, and direct evidence from human myocardial tissue is essentially absent. The metformin experience offers a cautionary lesson: in a randomized trial, metformin preserved peripheral mitochondrial respiration to some extent yet failed to demonstrate clear cardiac benefit, implying that biologically plausible interventions may falter when cardiac target engagement is never confirmed. Peripheral surrogate markers, in other words, may not faithfully reflect what is happening inside the myocardium. Any future therapy built on modulating selective autophagy will need pharmacodynamic readouts drawn from cardiac tissue itself, together with careful attention to dose, timing, and the checkpoint at which the pathway has failed. Until such tools exist, the checkpoint framework offered by Tian and colleagues serves less as a treatment manual than as a map of where the search should concentrate.

Subject of Research: Selective autophagy mechanisms in doxorubicin-induced cardiotoxicity

Article Title: Mitophagy and ER-phagy in doxorubicin-induced cardiotoxicity: mechanisms, crosstalk, and therapeutic implications

Article References: Tian, Y., Chang, A., Guo, Z., Zhou, H., Chang, X., & Wu, J. (2026). Mitophagy and ER-phagy in doxorubicin-induced cardiotoxicity: mechanisms, crosstalk, and therapeutic implications. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.022

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.022

Keywords: doxorubicin, cardiotoxicity, mitophagy, ER-phagy, autophagy, cardio-oncology, heart failure, chemotherapy, doxorubicin-induced, mechanisms, crosstalk, therapeutic

The scale of the problem is enormous. According to GLOBOCAN 2022 estimates from the International Agency for Research on Cancer, roughly 20 million new cancer cases occur worldwide each year, and solid tumors account for more than 90 percent of them. Lung, breast, colorectal, prostate, and gastric cancers alone make up 45.8 percent of global incidence. Immune checkpoint inhibitors have delivered durable responses in selected solid tumors, while CAR-T therapy remains largely investigational outside blood cancers. Against this backdrop, NK cell-based immunotherapy has attracted attention for its widely recognized low-risk profile and its potential as an off-the-shelf product.

But solid tumor patients are not the same population as hematologic cancer patients. They tend to be older, with lung and gastrointestinal tumors typically appearing at 60 to 70 years of age, and they carry a heavier burden of cardiovascular comorbidities, including hypertension in 26.0 percent, coronary heart disease in 7.8 percent, and heart failure in 3.3 percent. Prior anthracycline chemotherapy or thoracic radiotherapy often leaves the myocardium in a pre-injured state. Because immune checkpoint inhibitors and CAR-T cells can both trigger cardiovascular toxicity through mechanisms such as cytokine release syndrome, the authors argue that as NK cell strategies expand into solid tumors, their cardiac safety must be comprehensively evaluated before clinical translation proceeds.

NK cells kill through a coordinated set of molecular pathways. The activating receptor NKG2D binds stress-induced ligands such as MICA/B and ULBPs on tumor cells, natural cytotoxicity receptors NKp30, NKp44, and NKp46 recognize tumor-specific antigens, and CD16 mediates antibody-dependent cellular cytotoxicity. Once activated, NK cells release perforin and granzymes to punch pores in target-cell membranes, or trigger apoptosis through death ligands such as FasL and TRAIL. They also secrete interferon-gamma and tumor necrosis factor-alpha to recruit dendritic cells and T cells. Crucially, inhibitory receptors such as KIR and NKG2A recognize MHC class I molecules on healthy tissue, generating tolerance and limiting autoimmune injury.

The tumor microenvironment, however, systematically disarms this arsenal. High concentrations of TGF-beta and IDO suppress NK cell activation and proliferation, while nutrient deprivation, hypoxia, and metabolic byproducts such as lactate and adenosine further erode cytotoxic function. Upregulation of HIF-1alpha in solid tumors induces mitochondrial dysfunction in NK cells and inhibits aerobic glycolysis, causing energy-metabolism failure. Tumor-infiltrating NK cells also upregulate inhibitory checkpoints including PD-1, TIM-3, LAG-3, and TIGIT. Single-cell atlases of breast cancer and hepatocellular carcinoma have identified exhausted NK subsets with high expression of NR4A family genes and KLRC1, and these patients tend to have poorer prognoses.

Three therapeutic strategies aim to reverse this exhaustion. Genetic engineering, most notably chimeric antigen receptor NK cells (CAR-NK), equips NK cells with tumor-antigen-specific receptors; genome-wide CRISPR screening has identified negative regulators such as MED12, ARIH2, and CCNC whose knockout enhances metabolic adaptability, and chemokine receptors such as CXCR4 can be introduced to improve tumor infiltration. Antibody-mediated approaches, including bispecific and trispecific immune-cell engagers that bridge tumor antigens and CD16, as well as novel trispecific nanobodies targeting PD-L1, 4-1BB, and NKG2A, have significantly inhibited tumor growth in preclinical models. Cytokine and metabolic regulation, from IL-15 superagonists to intermittent fasting-induced fatty acid oxidation, offers a third route to restoring NK cell fitness.

The advantages of NK cells over T cells are multidimensional. They recognize cells that have lost MHC class I expression, a common consequence of genomic instability in solid tumors, without needing HLA-restricted antigen presentation. Their low risk of graft-versus-host disease and lack of HLA-matching requirements make them candidates for true off-the-shelf products, in contrast to the individualized CAR-T manufacturing process that takes at least three weeks. NK cells can be derived from cord blood, peripheral blood, induced pluripotent stem cells, or immortalized NK-92 cell lines, enabling standardized scaled production. They also rely more on oxidative phosphorylation than glycolysis, giving them better energy efficiency and fatigue resistance in the hostile tumor microenvironment, and their endogenous interferon-gamma can reprogram tumor-associated macrophages from a tumor-promoting M2 phenotype to an antitumor M1 phenotype.

Safety data so far support this optimism. CAR-NK therapy has shown extremely low incidence of cytokine release syndrome and neurotoxicity, with no definitive reports of grade 3 or higher CRS or immune effector cell-associated neurotoxicity syndrome to date. But the review warns that cardiotoxicity is broadly relevant across immunotherapies, and the safety advantages of NK cells should not be mistaken for absence of risk. Immune checkpoint inhibitor-related cardiotoxicity occurs in roughly 1 to 2 percent of patients with a fatality rate of up to 46 percent, significantly higher than myocardial injury from conventional chemotherapy. In CAR-T treatment, cardiovascular adverse events occur in 20.5 percent of patients, with hypotension and tachycardia presenting as hyperacute events within a median of 6 to 21 days.

The mechanisms of immune-mediated cardiac injury offer a preview of what could go wrong with NK cells. Cytokine release directly damages myocardial mitochondria and disrupts calcium homeostasis through IL-6, TNF-alpha, and interferon-gamma, while activating endothelial cells and inducing microvascular obstruction. Alpha-myosin-specific T cells can drive myocarditis, although TCR sequencing suggests most expanded clones target unknown cardiac antigens, challenging the universality of molecular mimicry. A positive-feedback loop between CCR2-positive macrophages and CD8-positive T cells, mediated by the IL-12b/TNF/interferon-gamma axis, remodels the myocardial immune microenvironment, and NLRP3 inflammasome activation triggers gasdermin-E-dependent pyroptosis and release of mitochondrial DNA that activates the cGAS-STING pathway, causing irreversible tissue damage.

For NK cells specifically, several theoretical risks emerge. Although NK cells secrete less IL-6 and IL-1-beta than activated T cells, and their CRS profile is dominated by interferon-gamma, GM-CSF, and TNF-alpha with typically mild grade 1 to 2 manifestations, even mild CRS can trigger capillary leak syndrome, reducing effective circulating blood volume and myocardial perfusion. TNF-alpha downregulates SERCA2a and promotes ventricular remodeling. In mouse models of acute myocardial infarction, mature NK cells massively infiltrate ischemic myocardium through a CCR2-dependent pathway and their granzyme B directly induces cardiomyocyte apoptosis, while granzyme B can also enter vascular smooth muscle cells without perforin assistance. HER2, a common CAR-NK target antigen, has basal expression in normal cardiomyocytes, and although preclinical studies have not shown toxicity against nonmalignant HER2-positive cells, those conclusions rest on short-term in vitro co-culture that cannot simulate the long-term in vivo immune environment.

Engineered persistence introduces further uncertainty. IL-15 and IL-21 both signal through the JAK1/JAK3-STAT5 axis, which in pressure-overload heart failure models directly drives fibroblast activation and type I collagen deposition. Chronic low-grade IL-15 exposure from CAR-NK cells persisting in vivo for several weeks may induce subclinical interstitial remodeling, and IL-15 has been shown to enhance NK cell glycolysis, potentially creating energy competition with cardiomyocytes that depend on oxidative phosphorylation. Combination with PD-1 inhibitors may amplify interferon-gamma-driven cardiomyocyte iNOS expression and nitric oxide production, while prior anthracycline chemotherapy leaves mitochondria leaking reactive oxygen species that can create a second hit when immunotherapy triggers overlapping autoimmune and inflammatory responses.

The knowledge gaps are stark. No prospective, multicenter study dedicated to the cardiovascular safety of NK cell products has yet been conducted; all reports of arrhythmia, heart failure, or myocarditis are scattered across case reports and secondary endpoint analyses. The CTCAE v5.0 grading system classifies events by absolute values alone, overlooking temporal dynamics and recovery trajectories, so subclinical injuries go underreported. Median follow-up in most NK cell trials is less than two years, while delayed cardiomyopathy and immune-mediated vasculitis often manifest years to more than a decade after treatment. Biomarker cutoffs for troponin and NT-proBNP validated in CAR-T contexts have not been established for CAR-NK, and advanced imaging parameters such as cardiac magnetic resonance T1 values and global longitudinal strain have not been formally incorporated into any NK cell trial.

The review proposes a path forward anchored in cardio-oncology collaboration. Baseline risk stratification should integrate the HFA-ICOS score with solid-tumor-specific factors such as chronic hypoxia and malnutrition, and with clonal hematopoiesis of indeterminate potential, an emerging biomarker associated with IL-6-driven endothelial activation after immune stimulation. Dynamic monitoring should combine high-sensitivity troponin, NT-proBNP, electrocardiography, and cardiac magnetic resonance, with baseline ferritin and IL-6 levels included as validated predictors of CRS-related cardiac dysfunction. The microRNA miR-145, negatively correlated with IL-6 and TNF-alpha, deserves evaluation as a diagnostic and potentially cardioprotective marker. For confirmed immune-related myocarditis, pulse methylprednisolone followed by mycophenolate mofetil maintenance is recommended, while tocilizumab should be reserved for CRS-associated cardiac dysfunction to avoid excessive suppression of antitumor immunity.

Deeper cardiovascular monitoring also raises ethical tensions around economic burden, psychological anxiety, and privacy, requiring a balance between scientific rigor and patient wellbeing. Elevating cardiovascular safety to a core dimension of efficacy evaluation could drive developers to optimize NK cell product design at the source. If those gaps are filled, the authors conclude, NK cell-based immunotherapy could become a more efficient, safer, shorter-cycle, and lower-cost option in solid tumor therapy, but only once its cardiac risks move from inference to evidence.

Subject of Research: NK cell-based immunotherapy for solid tumors and its cardiovascular safety

Article Title: Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety

Article References: Chen, J., Shen, J., Fu, X., Jiang, M., Liu, R., Qiao, Q., & Hu, Y. (2026). Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety. Frontiers in Cell and Developmental Biology, 14, Article 1927923. https://doi.org/10.3389/fcell.2026.1927923

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1927923

Keywords: NK cells, CAR-NK, solid tumors, immunotherapy, cardiotoxicity, cytokine release syndrome, tumor microenvironment, immune checkpoint inhibitors, cardio-oncology, granzyme B, IL-15, myocarditis

The study, published in Frontiers in Cancer Control and Society, drew on four years of data from the National Health Interview Survey (NHIS), an ongoing household survey run by the National Center for Health Statistics since 1957. Researchers led by Robina Josiah Willock of Morehouse School of Medicine analyzed responses from 2,495 women with self-reported breast cancer surveyed between 2019 and 2022, after excluding 250 questionnaires with more than 15 percent missing data. Because the NHIS underwent a comprehensive redesign in 2019, the four survey years are directly comparable, giving the team a nationally representative snapshot of the civilian, non-institutionalized population.

The outcome measure was deliberately broad. A survivor was counted as having cardiovascular disease if she reported a physician-confirmed diagnosis of any one of four conditions: angina, stroke, myocardial infarction, or coronary artery disease. The researchers then split the survivors into five cohorts based on time since diagnosis — less than one year, one to under five years, five to under seven years, seven to under ten years, and ten or more years — and examined how cardiovascular disease prevalence shifted across the survivorship trajectory.

The pattern was striking. Among women diagnosed less than a year earlier, 16.4 percent reported cardiovascular disease, a figure that likely reflects the acute cardiotoxic effects of chemotherapy and radiotherapy during active treatment. Prevalence then fell to 10.5 percent in the one-to-five-year cohort and 11.0 percent in the five-to-seven-year group. But after the seven-year mark, the curve bent sharply upward: 13.8 percent of survivors seven to ten years out reported cardiovascular disease, and among those surviving a decade or longer — the largest cohort, with 1,359 women — the figure reached 19.1 percent, the highest of any group.

That inflection point matters because it lands almost exactly where formal surveillance ends. Current U.S. breast cancer follow-up guidelines call for yearly mammograms for the first five years, physical exams every three to six months during the first three years, and every six to twelve months in years four and five. After year five, survivors are generally told they can return to routine annual care. The American Society of Clinical Oncology does recommend an echocardiogram within six to twelve months after treatment for asymptomatic patients at elevated cardiovascular risk, but beyond that horizon, enhanced cardiac monitoring largely reverts to what is standard for older women who never had cancer.

To understand who was most at risk, the team first ran Wald chi-square tests across seventeen sociodemographic, behavioral, and clinical variables. Thirteen were statistically significant, including employment status, marital status, delayed medical care, diabetes, body mass index, physical activity, cholesterol, hypertension, smoking history, self-rated health, age, and years of survivorship. Insurance status, education, race, and recency of a doctor’s visit were not, and were dropped from the final model. The researchers then built a forward stepwise logistic regression — a technique that adds and removes predictors in turn to produce the most parsimonious set of variables — which showed strong overall fit, with a likelihood ratio of 16.51 and a c-statistic of 0.754.

The regression results quantified the risks with unusual granularity. Women aged 85 and older had 9.75 times the odds of cardiovascular disease compared with those under 45, and women aged 66 to 84 had 4.24 times the odds. Survivors who had delayed medical care for a year or more because of cost or other barriers were 79 percent more likely to report cardiovascular disease. Hypertension nearly doubled the odds, raising them by 106 percent. Perhaps most striking was the weight of self-rated health: women describing their health as fair or poor had 8.05 times the odds of cardiovascular disease compared with those rating their health excellent, while those rating it good or very good had 2.41 times the odds. Women who had smoked at least 100 lifetime cigarettes showed a 28 percent increase in odds, a trend that fell just short of conventional statistical significance.

Some findings defied expectations. Insurance status, education, and race and ethnicity — factors repeatedly implicated in cardiovascular outcomes in prior research — showed no statistically significant association in this sample. The authors caution that this may be an artifact of sampling: roughly 84 percent of respondents without cardiovascular disease and 83 percent of those with it identified as white, leaving the survey underpowered to detect disparities affecting Black, American Indian, and Alaska Native women. That gap is consequential, because Black breast cancer survivors are known to experience higher cardiotoxicity, earlier onset of cardiovascular symptoms, and a 40 percent higher breast cancer mortality rate than white women, while American Indian and Alaska Native women face elevated mortality despite lower incidence.

The biological logic behind the survivorship curve is well established. Anthracyclines and fluoropyrimidines can trigger endothelial dysfunction and severe cardiac damage; methotrexate and fluorouracil have been linked to congestive heart failure; and chest radiotherapy disrupts coronary endothelium, raising the risk of coronary artery disease and subsequent hypertension. Layered on top of treatment effects are the shared risk factors that breast cancer and cardiovascular disease have in common — aging, hypertension, diabetes, hyperlipidemia, smoking, and sedentary lifestyles — which compound over the years as survivors age out of intensive oncology follow-up and back into general primary care.

The authors argue the data demand a paradigm shift: cardiovascular screening for breast cancer survivors should be lifelong and risk-stratified according to treatment type and individual health profiles, not capped at five years. Primary care physicians, who see survivors across the continuum of care, are positioned to lead that effort by managing hypertension, diabetes, and cholesterol with widely available medications, counseling on smoking, nutrition, and physical activity, and coordinating with cardio-oncology specialists when needed. Prior research suggests survivors want exactly this kind of lifestyle guidance but often do not receive it clearly. With the population of long-term survivors growing as treatment improves, the study’s central message is hard to ignore: surviving breast cancer is not the finish line — it is the beginning of a decades-long commitment to the heart.

Subject of Research: Cardiovascular disease risk among female breast cancer survivors in the United States

Article Title: Cardiovascular disease risk among female breast cancer survivors: findings from the National Health Interview Survey (2019–2022)

Article References: Josiah Willock, R., Nabi, S. R., Parks, D. C., Qaseem, B. A., & Miles, M. A. (2026). Cardiovascular disease risk among female breast cancer survivors: findings from the National Health Interview Survey (2019–2022). Frontiers in Cancer Control and Society, 4, Article 1628255. https://doi.org/10.3389/fcacs.2026.1628255

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1628255

Keywords: breast cancer, cardiovascular disease, cancer survivors, cardio-oncology, NHIS, hypertension, smoking, social determinants of health, survivorship care, cardiotoxicity, health disparities, logistic regression

At the center of this emerging field sits a deceptively simple question: how do you test whether a cancer drug will disrupt the heartbeat without putting a patient in danger? The answer, for now, lies in the laboratory. Two categories of harm dominate the concern. The first is arrhythmia, the dangerous derangement of the heart’s electrical rhythm, which in its worst form can trigger sudden cardiac arrest. The second is contraction dysregulation, in which the mechanical beating of heart cells weakens or desynchronizes, foreshadowing the pump failure clinicians know as cardiomyopathy. Both can be modeled in vitro, in dishes of beating heart cells, but the accuracy of those models depends entirely on the tools used to interrogate them, and a recent review published in Frontiers in Electronics argues that those tools are overdue for an upgrade.

The current benchmark for preclinical rhythm safety testing is the Comprehensive in vitro Proarrhythmia Assay, or CiPA, an initiative launched in 2013 after a string of drugs were withdrawn from the market for causing fatal arrhythmias. CiPA replaced the old, blunt instruments of cardiac safety pharmacology with a tiered strategy that combines in vitro measurements, computer simulations, and clinical evidence to evaluate proarrhythmic risk with far greater specificity and sensitivity than legacy assays. Its scope deliberately stretches across a broad range of pharmaceutical compounds, and that includes chemotherapeutics, making it the natural starting point for anyone trying to predict how a cancer drug will behave in the electrical circuitry of the heart.

Under CiPA, the recommended in vitro toolbox includes several distinct technologies for measuring the electrical activity of heart cells. Transmembrane potential can be recorded directly through patch clamp techniques, including their automated, high-throughput variants, which offer exquisite sensitivity to the ion channel currents that drive each heartbeat. Impedance measurements track how cells deform as they contract, providing a window into mechanical function. Voltage-sensitive optical assays, including voltage indicator dyes and genetically encoded voltage indicators, convert electrical activity into light that cameras can capture across an entire cell culture at once. Alongside these, microelectrode arrays occupy a privileged position, reading out the extracellular electrical field generated by spontaneously beating cardiomyocytes through dozens or hundreds of embedded electrodes.

Critically, CiPA also specifies what the cells should be. The framework recommends pairing these measurement techniques with human induced pluripotent stem cell derived cardiomyocytes, abbreviated hiPSC-CMs, cells that begin as a patient’s own skin or blood cells before being reprogrammed into an embryonic-like state and coaxed into becoming beating heart muscle. This matters enormously for precision cardio-oncology, because hiPSC-CMs can be derived from individual cancer patients, meaning a cardiologist could one day test a chemotherapy regimen against a cellular replica of that specific patient’s heart before committing to a treatment plan. The combination of human genetics and laboratory throughput is what gives the modern approach its promise, and its urgency, as immunotherapies with novel cardiac side effects enter widespread clinical use.

Herein lies the gap the review identifies. While CiPA offers a mature framework for drug-induced arrhythmia, there are currently no guidelines in place for the in vitro assessment of cancer treatment induced arrhythmia specifically, no standardized protocols for evaluating contraction dysregulation caused by oncology drugs, and no agreed-upon methods for testing cardiotoxicity arising from cell-based cancer therapies, a rapidly growing class of treatments including engineered immune cells. Cancer therapy is not simply another branch of general pharmacology; chemotherapeutic and immunotherapeutic agents act through mechanisms that differ fundamentally from conventional small-molecule drugs, and the patient populations receiving them, the very young and the very old, have cardiac physiology that standard testing may not capture. Without standardized assays, each laboratory improvises, results are difficult to compare, and genuinely risky therapies may pass through the cracks.

The review’s central argument is that microelectrode arrays, or MEAs, are the technology best positioned to close that gap. A microelectrode array is exactly what the name implies: a dish, often glass or a flexible polymer substrate, embedded with a grid of microscopic electrodes that sit beneath or around a culture of cardiomyocytes. As the cells beat spontaneously, each depolarization generates an extracellular electrical signal that the electrodes record in real time, producing a continuous stream of data on firing rate, beat-to-beat timing, conduction velocity across the culture, and the emergence of irregular rhythms that signal proarrhythmic danger. Because the measurement is noninvasive, the same culture can be monitored for days or weeks, allowing chronic exposure studies that mimic real-world treatment courses rather than single-dose snapshots.

What elevates MEAs from useful to potentially transformative, the authors contend, is their capacity for simultaneous, multiparameter monitoring. Modern MEA platforms can track the electrophysiological activity of the culture, its contractile behavior, and morphological changes in the cells themselves, all within a single experiment. That matters because cancer treatment cardiotoxicity rarely announces itself through one channel alone. A drug might subtly slow conduction before it destabilizes rhythm, or impair contractile force while the electrical waveform still looks superficially normal. An assay that measures only one parameter can miss the early warning signs, whereas a platform that watches electricity, mechanics, and cell structure at once can build a composite picture of cardiac health, catching deterioration earlier and characterizing its mechanism more completely. Applied to both chemotherapeutic and immunotherapeutic agents, this integrated approach could form the backbone of the standardized testing protocols that cardio-oncology currently lacks.

The trajectory of the technology reflects its own history. Microelectrode arrays were born in classical electrophysiology, where they served for decades as a workhorse for recording neuronal and cardiac activity in slices and cultures. Their migration into cardiotoxicity testing represents both a technical and conceptual evolution: from observing what heart cells do naturally, to predicting what drugs will do to them. Combined with automated analysis, increasingly sophisticated human cell models, and the patient-specific potential of hiPSC-CMs, MEAs are evolving from a research instrument into a screening platform that could sit at the intersection of oncology and cardiology clinics, evaluating proposed cancer treatments against living human heart tissue before a single patient is exposed.

The stakes of getting this right are difficult to overstate. As cancer survival continues to improve, the population of long-term survivors living with treatment-damaged hearts grows in parallel, and pediatric patients cured of leukemia today may face decades of cardiovascular consequences tomorrow. A validated, standardized, in vitro pipeline for detecting cancer treatment induced arrhythmia and contraction dysregulation before clinical exposure would not merely protect future patients; it could also rescue promising oncology drugs whose cardiac liabilities are identifiable and manageable if caught early. The review’s message is that the tools exist, the cellular models exist, and the clinical need is urgent. What remains is the regulatory and scientific work of standardization, turning the humming electrodes of the microelectrode array into the sentinel that stands guard between a cancer cure and the heart that must carry the patient through it.

Subject of Research: In vitro assessment of cancer treatment-induced cardiotoxicity using microelectrode arrays

Article Title: Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessment

Article References: Karami, N., Knafl, S., Wanzenboeck, H. D., & Prado-López, S. (2026). Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessment. Frontiers in Electronics, 7, Article 1886715. https://doi.org/10.3389/felec.2026.1886715

Image Credits: AI Generated

DOI: 10.3389/felec.2026.1886715

Keywords: microelectrode arrays, cardiotoxicity, cardio-oncology, chemotherapy, immunotherapy, arrhythmia, CiPA, hiPSC-derived cardiomyocytes, patch clamp, contractility, drug screening, precision medicine

The research combined two complementary approaches. First, the team conducted a single-center retrospective case series of seven patients diagnosed and treated at Hospital del Mar between 2020 and 2025. Second, they performed a systematic review of the published literature in accordance with PRISMA 2020 guidelines, searching PubMed/MEDLINE and Embase for reports published between 2015 and 2025. Eligible studies included case reports, case series, letters, correspondence, and conference abstracts, but only those providing sufficient individual patient-level data were retained. This dual design allowed the investigators to anchor their analysis in the granular reality of their own clinical practice while simultaneously mapping the broader international experience recorded across dozens of medical centers.

The Barcelona series reveals a strikingly consistent clinical phenotype. All seven patients were male, with a median age of 81 years, underscoring that this syndrome tends to strike elderly patients who are simultaneously battling advanced malignancy. The most frequent underlying tumors were non-small cell lung cancer, accounting for 42.8 percent of cases, and urothelial carcinoma, accounting for 28.5 percent. The presenting manifestations were remarkably stereotyped: diplopia, ptosis, and dyspnea each appeared in 71.4 percent of patients. In practical terms, most of these patients arrived at the hospital complaining of double vision, drooping eyelids, and breathlessness, a triad that simultaneously implicates the eye muscles, the respiratory system, and, lurking beneath the surface, the heart.

Treatment in the case series was aggressive and multidisciplinary. Most patients received high-dose corticosteroids, given to 71.4 percent, alongside intravenous immunoglobulins, administered to 85.7 percent. An additional 85.7 percent were treated with non-steroidal immunosuppressive agents, reflecting the severity of the syndrome and the recognition that steroid monotherapy is often insufficient once myocarditis is established. This therapeutic escalation mirrors the logic used in other severe immune-related adverse events: when the immune system has broken tolerance in multiple organ systems at once, clinicians must suppress it rapidly and broadly while accepting the infectious and metabolic risks that such intensive immunosuppression carries in elderly, immunocompromised patients.

The systematic review dramatically expanded the evidence base, incorporating 71 studies comprising 103 patients. The demographics differed in some respects from the local cohort: the pooled median age was 71 years and 68.9 percent of patients were male. The tumor spectrum was broader as well, with melanoma leading at 35.9 percent, followed by renal cell carcinoma and non-small cell lung cancer at 16.5 percent each. Notably, melanoma patients, who were absent from the top of the Barcelona list, dominated the literature, likely reflecting the historical predominance of melanoma in early checkpoint inhibitor trials and the greater published experience with these patients in centers that pioneered immunotherapy.

Clinically, the pooled data echoed the local series with impressive fidelity. Ptosis was the most common presenting symptom, affecting 71.8 percent of patients, and generalized weakness affected 62.1 percent. The most frequently reported initial therapeutic regimen was methylprednisolone at one gram per day, used in 35.9 percent of published cases, and 52.4 percent of patients received additional non-steroidal immunosuppressive agents. These figures suggest that, across the world, clinicians converge on a similar strategy: pulse high-dose steroids first, then layer on adjunctive agents such as intravenous immunoglobulin, plasma exchange, or targeted immunosuppressants when the response is inadequate or the cardiac involvement is severe.

The underlying biology helps explain why these three conditions cluster together. Checkpoint inhibitors block inhibitory receptors such as PD-1 and CTLA-4, which normally restrain T cell activity and preserve self-tolerance. Animal and human studies have shown that PD-1 signaling protects against inflammation and myocyte damage in T cell-mediated myocarditis, so its pharmacological blockade can unleash autoreactive T cells against shared antigens expressed in cardiac and skeletal muscle. Because striated muscle antigens are immunologically related across heart and skeletal muscle, and because autoantibodies against the neuromuscular junction can co-emerge, the syndrome behaves less like three separate toxicities and more like a single, coordinated autoimmune storm directed at the neuromuscular and cardiovascular axis.

The clinical implications are sobering. The authors conclude that IM3OS is a rare, early-onset, clinically severe immune-related overlap syndrome with a high mortality rate, one that demands prompt recognition, structured multisystem assessment, close cardiorespiratory monitoring, and multidisciplinary management. The emphasis on early onset is critical: unlike many immune-related adverse events that emerge weeks to months into therapy, this overlap syndrome frequently appears within the first cycles of treatment, meaning that oncologists, emergency physicians, and cardiologists must maintain a high index of suspicion whenever an immunotherapy patient develops new ocular symptoms, weakness, or dyspnea. Delayed diagnosis of the cardiac component is particularly dangerous, since fulminant myocarditis can cause arrhythmia and heart failure with little warning.

The Barcelona team stresses an important caveat that tempers any attempt to derive a definitive treatment algorithm. Current evidence remains entirely observational, drawn from case reports, case series, and institutional cohorts, and therefore does not allow conclusions regarding therapeutic superiority of any particular regimen. In other words, no randomized trial has yet determined whether high-dose steroids outperform moderate doses, or whether adding intravenous immunoglobulin or specific immunosuppressants changes survival in this syndrome. Randomized evidence is only beginning to emerge for checkpoint inhibitor myocarditis in general, with investigator-initiated trials such as ATRIUM, which evaluates abatacept in hospitalized patients, representing the first steps toward evidence-based therapy.

For patients and clinicians alike, the study’s practical message is vigilance and teamwork. Because IM3OS simultaneously involves organs managed by different specialists, optimal care requires coordinated input from medical oncology, cardiology, neurology, and autoimmune disease units, precisely the multidisciplinary structure that the Hospital del Mar team assembled for its own patients. published in the journal Supportive Care in Cancer, the analysis consolidates a fragmented literature into a coherent clinical picture and provides treating physicians with realistic benchmarks for presentation, demographics, and management. As checkpoint inhibitors continue to expand into earlier disease stages and broader populations, syndromes like IM3OS will inevitably be encountered more often, making structured recognition pathways, close cardiorespiratory surveillance, and continued research into mechanism and therapy an urgent priority for the growing population of patients whose lives depend on both the power and the peril of unleashed immunity.

Subject of Research: Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome

Article Title: Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review

Article References: Soriano, J., Martínez-Rubiño, M., Vicente Elcano, M., Pellicer Pérez, M., Bergua de Roque, A., Tanco Mulero, S., Miquel Bosh, C., Chen-Ye, A., Martín Ruiz, D., Torras-Vigo, I., Pellicer-Boiges, A., Ble Gimeno, M., Navarro-Gorro, N., Belarte-Tornero, L. C., Visa, L., Taus, Á., Rodriguez Martínez, J. E., Rodriguez-Vida, A., Arriola, E., & Llaberia-Torrelles, M. (2026). Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review. Supportive Care in Cancer, 34(11), Article 1108. https://doi.org/10.1007/s00520-026-11363-w

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11363-w

Keywords: immune checkpoint inhibitors, immunotherapy, myocarditis, myositis, myasthenia gravis, overlap syndrome, immune-related adverse events, cancer, cardio-oncology, systematic review, case series, corticosteroids